Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus low-dose prophylactic cranial irradiation versus durvalumab plus observation in stage III NSCLC
NL-OMON54172Phase 3Recruiting
- Sponsor
- NVALT
- Start
- Nov 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by NVALT. Primary endpoint: Cumulative incidence of brain metastases. Started Nov 2021; status: recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON54172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54172.